COMPARISON OF 2 DIFFERENT DOSES OF ONDANSETRON PLUS DEXAMETHASONE IN THE PROPHYLAXIS OF CISPLATIN-INDUCED EMESIS

Citation
D. Pectasides et al., COMPARISON OF 2 DIFFERENT DOSES OF ONDANSETRON PLUS DEXAMETHASONE IN THE PROPHYLAXIS OF CISPLATIN-INDUCED EMESIS, Oncology, 54(1), 1997, pp. 1-6
Citations number
22
Categorie Soggetti
Oncology
Journal title
ISSN journal
00302414
Volume
54
Issue
1
Year of publication
1997
Pages
1 - 6
Database
ISI
SICI code
0030-2414(1997)54:1<1:CO2DDO>2.0.ZU;2-F
Abstract
This study was conducted to evaluate the efficacy of two different dos es of ondansetron (8 mg vs. 24 mg) plus dexamethasone in the preventio n ofcisplatin (CDDP)-induced emesis and nausea (acute and delayed). Th e persistence of the anti-emetic efficacy during the second cycle of c hemotherapy was also assessed. Eighty patients receiving high-dose CDD P (>80 mg/m(2)) were randomized to have either ondansetron 8 mg plus d examethasone 20 mg (8 mg group) or ondansetron 24 mg plus dexamethason e 20 mg (24 mg group), given intravenously as a single dose before the CDDP infusion. From days 2-5, all patients received oral ondansetron 8 mg twice daily. Seventy-five patients (38 in the 8 mg group and 37 i n the 24 mg group) were evaluable for analysis. Among these, there wer e 24 patients who received ifosfamide (IFO) on the 2nd day of treatmen t; these patients were evaluated separately for delayed emesis. Comple te protection from acute emesis was obtained in 26 (68.4%) and 26 (70. 3%) patients, in the two groups, respectively. Complete protection aga inst acute nausea was achieved in 23 (60.5%) and 24 (64.9%) patients, respectively. With respect to the delayed emesis, complete protection was achieved in 14 (56%) and 13 (50%) patients not receiving IFO and i n 4 (30.8%) and 3 (27.3%) of those receiving IFO. The figures for the delayed nausea were: 12 (48%) and 13 (50%), 2 (15.4%) and 2 (18.2%), r espectively. Similar protection against emesis and nausea was recorded during the second cycle of chemotherapy. Both regimens have the same efficacy and thus, taking into account the cost-effectiveness, 8 mg of ondansetron plus dexamethasone in a single intravenous dose should be used for the prevention of high-dose CDDP-induced emesis.